New data of the real clinical practice confirms low incidence of major bleeding when using rivaroxaban in patients with non-valvular atrial fibrillation
New data of the real clinical practice confirms low incidence of major bleeding when using rivaroxaban in patients with non-valvular atrial fibrillation
Saved in:
| Main Author: | article Editorial |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Столичная издательская компания
2015-11-01
|
| Series: | Рациональная фармакотерапия в кардиологии |
| Online Access: | https://www.rpcardio.online/jour/article/view/332 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Association of rivaroxaban and apixaban therapy with major ischemic or bleeding events in patients with atrial fibrillation. Retrospective cohort real-world evidence study. Press release
by: article Editorial
Published: (2022-03-01) -
Association of Rivaroxaban vs Apixaban With Major Ischemic or Hemorrhagic Events in Patients With Atrial Fibrillation
by: article Editorial
Published: (2022-03-01) -
CLINICAL AND ECONOMICAL COMPARISON OF RIVAROXABAN AND APIXABAN USE IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION
by: S. V. Nedogoda, et al.
Published: (2017-03-01) -
Real-world cost-effectiveness of rivaroxaban and apixaban vs VKA in stroke prevention in non-valvular atrial fibrillation in the UK
by: Kevin Bowrin, et al.
Published: (2020-01-01) -
Rivaroxaban in stroke prevention in patients with non-valvular atrial fibrillation: what facts are important for the clinician?
by: I. S. Yavelov
Published: (2025-08-01)